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Abstract 
Fatty acid (±) 7-HDHA was recently identified as an endogenous ligand for 
PPARa/g receptors by one of our collaborators Dr. Henry Krause group. While this 
discovery is promising in understanding PPARs mechanism of effects and related 
diseases (Alzheimer’s disease, cerebral ischemia, retina inflammation, etc.), the study of 
7-HDHA in relation to PPARs has been hampered by the high cost and limited supply of 
7-HDHA.  
 
The total synthesis of 7-HDHA was attempted using four different strategies, and 
finally achieved in 11 steps in the longest reaction sequence, starting from commercially 
available (triisopropylsilyl)acetylene and 2-pentyn-1-ol. The overall yield of this synthesis 
was 12%. This concise route mainly relies on the one-step generation of three Z-double 
bonds with the semi-hydrogenation catalyst P2-Nickel, and a late-stage semi-
hydrogenation with Zn(Cu/Ag) reagent. The completion of this synthesis will now provide 
large quantities of 7-HDHA quickly, and thus enable extensive studies of PPAR – 7-HDHA 
interaction. 
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1. Introduction 
1.1 Use of Natural Products in Drug Discovery 
If a chemical exerts biological effects, it must have a molecular target in living 
organisms. The first step of drug discovery in a therapeutic area is usually to find a suitable 
drug target, such as receptors, enzymes or nucleic acids. These drug targets generally 
have complex roles, it is thus evidently important to have a thorough understanding of 
these biomacromolecules’ cellular functions and physiological effects. With the 
advancement of various genome projects and the field of proteomics, an ever-increasing 
number of proteins are newly discovered as potential targets.1 While it is encouraging that 
medicinal chemists now have many more targets to aim for, they do not have enough lead 
compounds to interact with the new targets.2 The difficulty nowadays is to identify 
molecules that could interact with potential targets, and thus answer crucial questions 
such as their fundamental functions.  
Since the dawn of the pharmaceutical industry, natural products have served as 
the single most important source for lead compounds. Before the era of high-throughput 
screening and genomics, more than 80% of drug molecules were either natural products 
or their derivatives.3 More recently (1994 to 2007), natural products still accounted for 
around 50% of all drug molecules.4,5 These natural products can come from a wide range 
of sources such as plants, animals and microbes, and they cover a broad spectrum of 
medical conditions.  
Moreover, all forms of life are in an uphill battle in fighting thermodynamics, Erwin 
Schrödinger once defined life as a system that resists decaying to disorder and 
equilibrium,6 such a battle costs energy. However, nature still spends much scarce energy 
in making many structurally elaborate molecules, from Darwin’s point of view, these 
molecules would normally have some sort of biological activity. In contrast to totally 
laboratory-made molecules, naturals products have a much higher chance to be bioactive, 
and to resemble biosynthetic intermediates or metabolites.   
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Another reason why natural product holds promises in medicine is their enormous 
structural and chemical diversity, to a degree no synthetic library can surpass. For 
example, the antimalarial drug artemisinin extracted from sweet wormwood contains a 
trioxane ring, which appears to be extremely unstable (Figure 1), a structure that is very 
unlikely and beyond chemists’ imagination for drug design.  This large collection of 
extremely novel compounds is of course invaluable; however, their structural complexity 
also makes their syntheses very difficult. Instead, natural products are usually extracted 
from natural sources - a time-consuming, costly and unproductive process. Therefore, a 
tremendous amount of effort has been made into the total syntheses of natural 
compounds in academia and industry. Furthermore, total synthesis can potentially provide 
access to a library of natural product’s analogues, which is extremely important in lead 
compound campaign and optimizing drug-target interactions.  
 
Figure 1. The structure of artemisinin, an antimalarial drug. 
 
1.2 Biological Motivation for the Synthesis of (±) 7-HDHA Synthesis 
PPARs (Peroxisome Proliferator-Activated Receptors) are a class of “adopted 
orphan” nuclear receptors that consist of PPARa, PPARd, and PPARg. It is believed that 
the PPARs family of receptors plays a major regulatory role in energy homeostasis and 
metabolic function,7 such as the metabolism of carbohydrates, lipids, and proteins.8 Also,  
various studies have shown that PPARs regulates cellular differentiation and development, 
and tumorigenesis etc.9–11 PPARs function as ligand-dependent transcription factors, 
namely, all PPARs heterodimerize with a retinoid X receptor (RXR), these heterodimers 
then bind to PPREs (PPAR Response Elements) within promoter regions of the target 
O
O
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genes, realizing the regulation of target gene expression.12 In the absence of a PPARs 
ligand, these heterodimers are associated with co-repressor complex and block the target 
gene transcription,13 whereas upon binding to an agonist ligand (Figure 2), the 
conformation of a PPAR is changed so that a new binding domain is created, allowing the 
recruitment of transcriptional co-activators that ultimately results in an increase in gene 
transcription.10  
 
Figure 2. The mode of action for PPARs family of nuclear receptors. The ligand-bound PPARs 
heterodimerize with an RXR receptor, which then recruits a transcriptional co-activator. This 
complex then binds to the promoter regions of the target genes, realizing the regulation of target 
gene expression. 
PPARa is highly expressed in brown adipose tissue and the liver,14,15 where it 
responds to various free fatty acids in different sensitivities and thus increases or 
decreases energy metabolism rates. For example, studies showed that PPARa is a 
positive regulator for fatty acid oxidation,16 lipid transport and metabolism, ketogenesis 
and gluconeogenesis.17–19 Also, gene expression studies revealed that PPARa is 
distributed in cerebral cortex, hippocampus, brain stem and retina.20,21 Another study 
suggested that hippocampus PPARa is essential to memory formation via transcriptional 
 4 
upregulation of CREB (cAMP response element-binding protein), a transcription factor 
capable of binding DNA and regulating gene expression.22 Subsequently, several novel 
potential endogenous ligands extracted from the hippocampus have been identified and 
shown to stimulate synapse formation by hippocampal neurons,23 these new additions of 
ligand have furthered our understanding of hippocampal neurogenesis. The neurogenic 
capacity of hippocampal neural stem/progenitor cells (NSPCs) depends on a balance 
between quiescent and proliferative states, where the activity of NSPCs is regulated by 
the rate of fatty acid oxidation that requires PPARa, which is highly upregulated in 
quiescent.24 Hence, the understanding of PPARa is also important for hippocampal 
neurogenesis studies since failing neurogenesis has been implicated in many 
neuropsychiatric diseases. 
The attention of PPARg has been focused on its relation to the promotion of 
adipogenesis in white and brown adipose tissue.25 Moreover, PPARg contributes to insulin 
sensitivity,26 and is important for anti-inflammatory in macrophages27 and other tissues 
such as the colon.28 Two recent reports demonstrated the crucial roles of PPARg in the 
brain that affect feeding, insulin sensitivity, and energy metabolism.29,30 Furthermore, 
PPARg has potential neuroprotective in various pathological states, such as cerebral 
ischemia and Alzheimer’s disease.31 Since it seems that PPARa and PPARg together play 
very important yet very different molecular and physiological roles in the central nervous 
system (CNS) comparing to their roles in other tissues, it is reasonable to assume the 
brain-expressed PPARs would have different ligands than their counterparts in peripheral 
tissues, not to mention the brain’s vastly different environment. Therefore, previously 
identified ligands and described PPARs-ligand interactions might have a little basis in the 
CNS, which calls the discovery of novel endogenous ligands and sequential study on 
PPAR-ligand interactions.  
As a group of treatable targets, a number of potent agonists and antagonists for 
PPARs have been identified from small molecule libraries,32 yet the PPARs are generally 
viewed as “sensors” for a variety of less potent but crucial endogenous ligands, particularly 
polyunsaturated fatty acids.33–35 However, the variety of lipids and potential endogenous 
ligands in different tissues has not been fully established. Moreover, there is still debate 
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on the values of many previously identified PPARs natural ligands. For example, 1) many 
showed low affinities to PPARg, including 13-hydroxyoctadecadienoic acid (13-HODE), 9-
HODE, 15-hydroxyeicosatetraenoic acid (15-HETE), 5-hydroxyeicosapentaenoic acid (5-
HEPA), etc.;36 2) although oleoylethanolamide is a potent ligand for PPARa, there is no 
evidence supporting its direct binding to PPARa;37,38 3) PPARg ligand, 15-deoxy-D-12,14-
prostaglandin J2 (15d-PGJ2), has much a lower physiological concentration than required 
for actual PPARs activation;39,40 and 4) nitroalkene derivatives of oleic acid (OA-NO2) and 
linoleic acid (LNO2) have the half-lives too short in our body to be the actual ligands.41  
Our collaborator at the University of Toronto, Dr. Henry Krause group recently 
isolated an omega-3 fatty acid, 7-hydroxyl docosahexaenoic acid (7-HDHA, Figure 3), 
from zebrafish brain and eyes, and mouse hippocampus and cerebellum. They 
demonstrated that 7-HDHA is an endogenous ligand for both PPARa and PPARg. In 
human neutrophils, 7-HDHA was biosynthesized from the oxidation of docosahexaenoic 
acid (DHA), mediated by 5-lipoxygenase (ALOX-5). When neutrophils were treated with 
an ALOX-5 inhibitor, the formation of 7-oxo-DHA and its hydroxy precursor 7-HDHA was 
completely suppressed.42 In vivo and in vitro-based assays were used to show that 7-
HDHA binds directly to both said receptors’ ligand binding sites, as a potent agonist for 
PPARa and a partial agonist for PPARg. More preliminary studies from Dr. Krause group 
indicated that in the brain, 7-HDHA stimulates the actions of PPARa in promoting 
hippocampal neuronal growth and synapse formation, which are associated with memory 
formation and regeneration. As for PPARg, 7-HDHA’s partial agonist ability was still able 
to stop the cyclin-dependent kinase 5 (Cdk-5) mediated phosphorylation at Ser273 in 
PPARg, which lowers both inflammatory and lipogenic activities.  
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Figure 3. The structure of (±) 7-HDHA 
These early results showcase many possible physiological roles for 7-HDHA in the 
brain, eye, and metabolism. They would help our understanding of corresponding 
diseases such as cerebral ischemia, Alzheimer’s disease, diabetes, obesity, etc., which 
in turn helps the development of possible therapeutic treatments. The planned study on 
PPARs-7-HDHA interactions requires a steady and substantial supply of 7-HDHA, which 
has been hampered by its extremely high price and limited commercial supply. For 
instance, one commercial supplier prices the racemic 7-HDHA at 65 USD per 25 µg, and 
it has only 2.2 milligrams in stock. The completion of the total synthesis of 7-HDHA will 
now enable extensive studies of this system, and will prove useful in drug discovery efforts 
targeting the PPAR family of nuclear receptors. 
 
1.3 Retrosynthetic Analysis of (±) 7-HDHA 
Despite its linear structure and the presence of only one stereogenic center, 7-
HDHA presents significant synthetic challenges. For instance, the -OH group at the 7-
position quickly became a disadvantage during the first and seemingly most 
straightforward synthesis plan. Moreover, 7-HDHA possesses six olefin moieties, 
including skipped, isolated and conjugated alkenes, five of which are in Z configuration 
and are prone to isomerization and conjugation.  
The retrosynthetic analysis of (±) 7-HDHA began with recognizing that the 
carboxylic acid group on C-1 can be revealed by hydrolysis reaction of the corresponding 
OH
OH
O
7-hydroxyl docosahexaenoic acid 
(±) 7-HDHA
 7 
ester (Scheme 1). Similarly, the hydroxyl group on C-7 can be exposed by the 
deprotection of its silyl ether assisted by a fluoride source. The protection of the alcohol 
and acid group could potentially reduce their acidic proton’s interference in many reactions 
and thus prevent unwanted side reactions. Next, in the protected 7-HDHA 1, there are two 
conjugated double bonds between C-8 and C-11. The olefin between C-10 and C-11 is in 
Z-configuration and could be accessed by Z-selective semi-hydrogenation reactions from 
corresponding alkyne 2, such methods have significant precedent in the literature, 
especially in the realm of heterogeneous hydrogenations.  
 
Scheme 1. The first part of the retrosynthetic analysis for (±) 7-HDHA. 
In compound 2, the sp2-sp bond between C-9 to C-10 can be forged by a 
Sonogashira coupling reaction.  The two coupling partners are a vinyl iodide (C-1 to C-9 
fragment) and a terminal alkyne (C-10 to C-22 fragment) (Scheme 2). For the vinyl iodide 
fragment, we devised two strategies to access it Z-olefin between C-4 and C-5. The first 
strategy involves an 8-membered lactone formation (compound 3), this method relies on 
locking the double bond Z-configuration by confining it within a ring structure. Normally in 
a chain structure, simple Z-double bond is less stable more its E counterpart, however, 
double bond Z-geometry is vastly more preferred when present in a small or medium-
sized ring. Thus, we envisioned that the Z-olefin between C-4 and C-5 can be readily 
formed selectively if we enclose it into a ring. There are several methods to realize the 
simultaneous formations of the ring and the olefin, with ring closing metathesis being the 
most straightforward one.  
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The other strategy to access the Z-double bond in the C-1 to C-9 fragment relies 
on a direct and Z-selective olefination method to give a chain structure (compound 4). 
Without the thermodynamic drive created in the first “ring strategy”, this “chain strategy” 
requires a method that kinetically favors the formation of a Z-double bond. A well-studied 
and reliable example for such Z-selective olefination is Wittig reaction, using a non-
stabilized phosphonium ylide. 
 On the other hand, the C-10 to C-22 fragment (compound 5) also presents some 
challenges. First of all, the olefin synthesis needs to be Z-selective, and mild enough to 
accommodate the skipped olefins, since harsh conditions might isomerize the skipped 
olefins into either E-olefins or conjugated systems. Transition metal-catalyzed, 
heterogeneous semi-hydrogenation of alkynes is one of the most canonical methods for 
Z-olefin synthesis. More importantly, it should allow us to form all three Z-olefins in a single 
step from corresponding skipped tetrayne. Another challenge is that the semi-
hydrogenation needs to be selective so that the terminal alkyne is unaffected. Fortunately, 
this can be achieved simply by replacing the terminal alkynyl proton with a silyl protecting 
group.  
 
Scheme 2. The second part of the retrosynthetic analysis for (±) 7-HDHA. 
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2. Total Synthesis of (±) 7-HDHA 
2.1 First Synthetic Approach Towards Fragment S1 
The planned synthesis of fragment 3 required an efficient method to construct an 
eight-membered ring, and ideally, the ring formation would simultaneously install the Z-
olefin between C-4 and C-5. This approach features a ring-closing metathesis (RCM) to 
accomplish this goal. A fast route to access the RCM precursor diene 7 was executed.  
Compound 8 was initially made by two sequential reactions (Scheme 3); 1) 
standard silylation of propargyl alcohol 6 by chlorotrimethylsilane to give 7 and 2) transfer 
of the silyl group from the oxygen atom to the terminal sp-hybridized carbon atom to give 
the volatile alcohol 8. Although these two sequential reactions were smooth 
transformations, the combined yield over two steps was only about 50%. The yield was 
improved by first treating compound 6 with 3.0 equivalents of the strong base, 
ethylmagnesium bromide, to result in the formation of a dianionic species, which was then 
quenched with TMSCl.  Therefore compound 8 was realized in a single step with an almost 
2-fold increase in yield.43  
 
Scheme 3. The two synthetic methods to alcohol 3. 
 The alkyne moiety in propargyl alcohol 8 was reduced by sodium bis(2-
methoxyethoxy) aluminum hydride (Red-Al) to give trans-hydrogenated allylic alcohol 9 
(Scheme 4), which was then oxidized to aldehyde 10 using the Cu-TEMPO catalytic 
system developed by Stahl and co-workers.44  
TMSO
H
HO
TMS
HO
H
TMSCl
imidazole
DCM
EtMgBr
THF, 0℃
76% 70%
3.0 equiv. EtMgBr, TMSCl, Et2O, 0℃
92%
6 7 8
 10 
 
Scheme 4. The synthesis of aldehyde 5. 
The alkyne reduction with Red-Al depends critically on the presence of the 
neighboring OH group. First, Red-Al deprotonates the alcohol to give intermediate 11 
(Scheme 5), then a hydride is delivered to the b carbon in an intramolecular fashion to 
result in a five-membered vinylaluminum ring 12. Then the trans-olefin 9 is formed by 
stereospecific substitution of a proton for aluminum upon quenching the intermediate with 
acid. It is worth noting that by applying this organoaluminium intermediate, other 
electrophiles (such as I2) have been used for functionalized olefin synthesis. 45 
 
Scheme 5. Mechanism of Red-Al reduction of 8. 
The (bpy)CuI/TEMPO catalytic system developed by Stahl and co-workers oxidizes 
primary alcohols to the corresponding aldehydes under extremely mild conditions.44 
Similar methods that use catalytic amount of TEMPO for alcohol oxidations were reported 
previously with various stoichiometric oxidants including electric current,46 NaOCl,47 
peroxy acid,48,49, etc. A more relevant alcohol oxidation method by using 
CuCl2/TEMPO/O2 system was also reported in the 1980s by Semmelhack and co-
workers.50 They proposed that their reaction proceeds through an oxoammonium cation 
intermediate (TEMPO+) that forms by CuII oxidation of TEMPO,51,52 the TEMPO+X- 
species then oxidizes alcohol to aldehyde (Scheme 6).53–55  
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Scheme 6. Semmelhack's mechanism for TEMPO-catalyzed aerobic alcohol oxidation. 
However, it is unlikely that (bpy)CuI/TEMPO catalytic system follows the above 
mechanism. Stahl and co-workers suggested that TEMPO+ is not involved as an active 
oxidant under their reaction conditions. Based on experimental evidence 1) Cull is 
incapable of oxidizing TEMPO to TEMPO+ under the reaction condition, especially when 
bound to bipyridyl ligand, and 2) TEMPO+ is not nearly kinetically competent enough to 
perform such fast oxidation. In turn, they suggested a pathway that involves CuII and 
TEMPO acting in concert to deliver a net two-electron alcohol oxidation. 56 Also, Stahl 
showed that the alcohol is oxidized by intramolecular concerted hydrogen atom transfer 
via a six-membered ring transition state, involving a h1-nitroxyl-Cu adduct (Scheme 7).57  
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Scheme 7. The mechanism for Cu/TEMPO-catalyzed aerobic alcohol oxidation suggested by 
Stahl and co-workers. 
Aldehyde 10 was treated with allylmagnesium bromide and delivered alcohol 13 
(Scheme 8). Then Steglich esterification between 13 and 4-pentenoic acid 14 mediated 
by DCC and a catalytic amount of DMAP furnished 7, the ring closing metathesis 
precursor.  
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Scheme 8.The synthesis of diene 15. 
It is worth mentioning that allylmagnesium bromide can only be formed in diethyl 
ether. It has been reported that allyl bromide reacts quantitatively with magnesium in THF 
to give 1,5-hexadiene through Würtz-type reaction.58 N,N’-Dicyclohexylcarbodiimide 
(DCC) was one of the first carbodiimides developed as a dehydration reagent to mediate 
ester and amide formation.59 The reaction’s neutral and mild reaction conditions have 
made it very popular especially in peptide synthesis,60 since the direct conversion from 
carboxylic acid to amide is difficult because the basic amine group tends to convert the 
acid into unreactive carboxylate. An efficient Steglich esterification requires the use of a 
catalytic amount of nucleophilic catalyst, usually DMAP, which acts as an acyl transfer 
agent because of its higher nucleophilicity than that of alcohols (Scheme 9). 
Dicyclohexylurea is always the stoichiometric byproduct in the DCC coupling reaction, and 
it cannot be visualized by UV light or staining the TLC plate, thus its removal is frequently 
problematic and requires multiple careful filtrations of the crude product before flash 
column purification.   
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Scheme 9. The mechanism of Steglich esterification. 
With ester 15 in hand, we attempted ring-closing metathesis (RCM) with Hoveyda-
Grubbs 2nd generation catalyst, however, neither TLC and crude NMR analysis showed 
product formation. Different ruthenium-based metathesis catalysts and various reaction 
conditions were used, unfortunately, none of them gave the desired product 16 (Scheme 
10).  
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Scheme 10. Attempted ring-closing metathesis and all ruthenium-based catalysts that were 
used. 
RCM reactions to access 5-, or 6-membered rings with very high yields are well 
documented. However, the formation of a medium-sized ring is challenging and often 
fails.61,62 It is safe to say that the majority of RCM reactions are largely governed by 
thermodynamics since every step in the mechanism is in principle reversible.63  
Two types of strains in a ring contribute to the overall ring strain, they are angle 
strain and transannular strain. Although larger-sized rings release angle strain, the 
transannular strain could increase due to the imperfect staggering of the substituents. This 
explains why the ring strains increase from seven- to nine-membered cyclic olefins 
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(Figure 4. A) and supports the fact that RCM often encounters problems for the formation 
of medium-sized rings.64 This notion is also supported by studies that explore the 
correlations between ring sizes and cyclization rates in stoichiometric lactonization 
reactions for saturated lactones.65,66 Although the values in Figure 4. B are for saturated 
lactones, they provide a useful illustration of the correlation between ring sizes and 
formation rates. In Figure 4. B, the entropic cost (DS¹, purple line) in a lactonization 
generally increases with increasing ring size, which can translate into the decrease of 
encounter probability of two ends of a chain required for cyclization. The enthalpic cost 
(DH¹, red line) reflects the lactone ring strain. Noticeably, eight- and nine-membered rings 
have the largest ring strain that offsets their reasonably high encounter probabilities, 
granting eight- and nine-membered rings the lowest rates of formation (green line). This 
rate retardation in metathesis is problematic because it increases the opportunity for 
competing catalyst decomposition, therefore, reduces yields or promotes side reactions.67 
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(B) 
Figure 4. A. Calculated strain energies for unsaturated, carbocyclic olefins of five to nine 
members;64 B. DS¹ profile (purple line, the entropic cost), DH¹ profile (red line, the enthalpic 
cost) and the formation rate (green line) of various sizes of saturated lactones in stoichiometric 
lactonization studies.65,66 Note: the formation rate (green line) is not referred by a Y-axis, only to 
show its general trend. 
 However, it is not to say 8- or 9- (may include 10-) membered rings are impossible 
to form via RCM, there are indeed many reported successful examples.68–73 Besides the 
catalyst design, one of the ways to achieve RCM for these “tough” ring sizes is to use high 
dilution of the reaction mixture.74 It is known that intermolecular metathesis (acyclic diene 
metathesis, ADMET) is a competing bimolecular process in RCM reactions, fortunately, 
this process can be kinetically suppressed by high dilution to avoid diene oligomerization. 
An intrinsic problem with high dilution is that the catalyst-substrate reaction is still 
bimolecular, whose rate will also be lowered by lowering the reaction concentration, giving 
time for catalyst decomposition. In our efforts, with Hoveyda-Grubbs 2nd and Grubbs 2nd 
catalysts, diene 15 was subjected to the concentrations of 5 mM, 3 mM, 2 mM and 1 mM 
in either DCM or toluene. Unfortunately, none of these conditions gave the desired RCM 
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product. To achieve 1 mM substrate concentration, 50 milligrams of diene 15 requires 200 
milliliters of solvent. Concentrations lower than 1 mM would be highly impractical but might 
be needed. In practice, we achieved the most vigorous dilution by adding both substrate 
and the catalyst solutions dropwise into the reaction mixture with the help of two syringe 
pumps. this protocol provides substrate concentration that is significantly lower than 1 mM. 
Unfortunately, it also did not give the desired product, even though high dilution reportedly 
worked in some challenging macrocyclizations.74  
Fortunately, there is a way to circumvent the oligomerization problem in RCM 
reactions. Other than cross-metathesis and RCM, ruthenium-based catalysts can also 
perform ring-opening metathesis polymerization (ROMP): also an equilibrium process 
between diene polymer/oligomer and cyclized product (RCM product). Therefore, if 
oligomers are inevitably formed during RCM reactions, they could in principle still be 
converted to cyclized products via ROMP equilibrium (Scheme 11).75,76 Although 
metathesis often is described as a fully reversible process, the loss of volatile ethylene 
molecules is irreversible under normal operating conditions, making the oligomerization 
and RCM irreversible processes. Fortunately, ROMP is fully reversible because it does 
not release ethylene, providing an indirect way to access RCM products. Applying the 
logic in Scheme 11, there are examples in the literature that use oligomers or dimers of a 
diene as the precursors to RCM when direct RCM failed to work.62 
 
Scheme 11. A general scheme of ring closing metathesis of a diene, including the direct RCM 
pathway and indirect ADMET-ROMP pathway. ADMET: acyclic diene metathesis; ROMP: ring-
opening metathesis polymerization. 
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Since ROMP is an equilibrium process, without redesigning the diene substrate or 
the catalyst, operational manipulations could be made to lead the equilibrium to shift 
towards either direction (ring or chain). Thus, it is important to know what governs the 
equilibrium constant in a ROMP reaction, and one can borrow from a related theoretical 
study by Jacobson and Stockmayer that considers the distribution of cyclic and linear 
polymers present at equilibrium in concentrated solutions.77 Ring formation by 
intramolecular reactions was a long-standing problem in linear polymer condensations. 
The study predicted a concentration-dependent ring-chain equilibrium in a reversible 
polymerization process, where high dilution would favor the ring formation and the high 
concentration would favor the polymer/oligomer formation. Because Jacobson-
Stockmayer theory makes a couple of ideal assumptions, such as it treats all rings as 
strainless and the cyclization as athermal, it is more of a general prediction, so each RCM 
case in real life will need specific measures.  
 Based on the Jacobson-Stockmayer theory, one can predict that there is no need 
to perform a cyclization reaction under extreme dilution throughout the whole course, as 
long as the final concentration reaches the “critical concentration” that leads the 
equilibrium to ring formation. Danishefsky and co-workers tested the use of Ziegler “infinite 
dilution”65 methods in RCM with Grubbs 2nd catalyst. Compared to reactions in which all 
reagents were added at once, the dropwise addition of diene (over a 7-hour period) to the 
catalyst solution in refluxing benzene had no influence on the RCM product yield.78 In his 
examinations, the final RCM yield solely depended on the final concentration, which 
confirms Jacobson-Stockmayer theory’s prediction, at least in some cases. This is very 
useful information because we do not have to use a highly diluted reaction mixture in the 
beginning. If oligomerization is kinetically favored, one could start the reaction at a much 
higher concentration so that oligomer-ring (ROMP) equilibrium quickly establishes, then 
one can dilute the reaction X times to reach the favored dilution for RCM product. the 
initial high reaction concentration would help catalyst-substrate reaction rate and reduce 
catalyst decomposition. We performed such a procedure, however, no desired product 
was seen after many attempts with different catalysts (Grubbs 2nd and Hoveyda-Grubbs 
2nd) and solvents (DCM and toluene, 40°C and 80°C). 
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 At this point, catalyst decomposition or deactivation in the reaction condition has to 
be considered. The most obvious catalyst deactivation is through the chelation of polar 
functionalities to the catalyst’s ruthenium metal center, this is a very common issue that 
has a minimal effect on readily-cyclized dienes, but can be extreme for more demanding 
substrates (Scheme 12).79  
 
Scheme 12. Two possible chelation modes for ruthenium with the polar functional groups in 
diene 15. 
 To inhibit this poisoning chelating effect, Lewis acids have been often used as co-
catalysts in RCM. In the case of an oxygen atom being a chelating element, an oxyphilic 
transition metal Lewis acid can be used, such as titanium isopropoxide,80–83 that could 
out-compete [Ru] and occupy the Lewis basic functionalities. However, upon treating our 
RCM reactions with either 0.3 equivalent, 1.0 equivalent or 2.0 equivalents of titanium 
isopropoxide, no beneficial effect was observed.  
There were some other efforts we made for this RCM reaction. They are: 1) A range 
of temperatures from room temperature (in DCM or toluene) to 110°C (in toluene); 2) 
addition of extra catalysts after the reaction showed no more change on TLC plates; 3) 
carrying out the reaction at static vacuum using 1,3,5-trimethylbenzene as solvent, to 
maximize the ethylene extrusion and, 4) vigorous degassing of the solvent (multiple 
freeze-pump-thaw cycles). None of the adjustments showed any promise, it seems that 
diene 7 is not compatible with our current RCM protocols, certainly not with Grubbs-class 
ruthenium catalysts in our system. Complications could come from the possibility of vinyl 
silane moiety participating in the catalytic cycle, or other ruthenium catalysts 
decomposition pathways, which is a very active research area. There are other metal 
complexes that can be used for metathesis, although Schrock’s molybdenum-based 
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catalysts are much more reactive metathesis catalysts than Grubbs’. It was avoided in our 
synthesis due to the extremely high cost and air/moisture sensitivity. We decided to 
explore other routes to access fragment 3.  
 
2.2 Second Synthetic Approach Towards Fragment 3 
To access a strained ring using RCM reaction from an acyclic diene is usually both 
entropically and enthalpically disfavored, which is the major problem in our hands. Instead 
of building from an acyclic system, ring expansion provides an alternative way for larger 
ring formation, and this process should be largely entropically neutral. The second 
approach to fragment 16 features a two-atom ring expansion via Claisen rearrangement, 
from a 6-membered to the target 8-membered ring (Scheme 13).  
 
Scheme 13. The retrosynthetic analysis of fragment 3 featuring a Claisen rearrangement. 
b-Hydroxyl ketone 19 was synthesized from an aldol condensation between 
aldehyde 5 and methyl vinyl ketone 18 (MVK) (Scheme 14). 
 
Scheme 14. Synthesis of b-hydroxyl ketone 19 via aldol condensation between aldehyde 10 and 
methyl vinyl ketone (MVK). 
Although it seems to be straightforward and classic aldol reaction, the use of MVK 
as nucleophile is very rarely described in the literature. The reaction is very sensitive to 
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the order of addition of reagents. First of all, MVK was added dropwise to LDA solution to 
ensure complete formation of MVK enolate without self-condensation; secondly, the 
formed MVK enolate was added dropwise to the solution of aldehyde 10 and AgBF4. In 
the literature, unfortunately, aldol condensation involving MVK 18 enolate either was very 
low yielding (addition to benzaldehyde at -78 °C, without any additive, 8% yield)84, or used 
inaccessible additives. Hong and co-workers described the aldol condensations between 
MVK enolate and aldehydes by using superstoichiometric amount of various exotic 
lanthanide(lll) Lewis acids, with up to 69% isolated yield (Lewis acid: TbCl3).84  
Another concern is that this aldol reaction produces the only stereogenic center 
present in the final product 7-HDHA. However, a literature search was disappointing for 
the possible enantioselective variant of the aldol reaction. The only example was a direct 
asymmetric Zn-aldol reaction of MVK using a catalytic amount of a dinuclear Zn-complex 
reported by Trost (Figure 5), with an average yield about 50% and moderate 
enantioselectivity.85,86  
 
Figure 5. The catalytic zinc complex used in Trost's direct asymmetric Zn-aldol reactions of 
MVK. 
There are also some methods that could be potentially used to achieve this aldol 
condensation. They include the use of arginine,87 immobilized oligopeptides on magnetic 
particles,88 and the pre-formation of silyl enol ether,89,90, etc. These methods all have 
limited substrate scopes and inaccessible materials.  
Nevertheless, b-hydroxyl ketone 19 was treated with tetramethylammonium 
triacetoxyborohydride [Me4N•BH(OAc)3] to produce diol 20 diastereoselectively (Scheme 
15). The use of triacetoxyborohydride to perform anti-reduction of b-hydroxyl ketones was 
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first described by Saksena and co-workers in 1983.91 They employed sodium 
triacetoxyborohydride [Na•BH(OAc)3], and envisioned an intramolecular hydride delivery 
directed by the b-hydroxyl group. The method was further developed and improved by 
Evans in 1987,92 and has been used widely and reliably in many syntheses.93,94  
 
Scheme 15. The synthesis of cyclic carbonate 20. 
 Triacetoxyborohydride itself can reduce aldehyde in the presence of ketone,95 this 
weak reactivity comes from the electron-withdrawing effect of the three acetoxy groups as 
well as the steric shielding of the B-H bond. The low hydride reduction potential is needed 
to minimize the interference of completing bimolecular reductions. However, the acetoxy 
group is a readily exchangeable ligand. The hydroxyl group could pre-associate with the 
reducing agent.  This leads to a relatively more electron-rich boron species that then 
reduces carbonyl group via a well-defined transition state, in an intramolecular fashion 
(Scheme 16).  
 
Scheme 16. b -hydroxyl directed anti-reduction of a ketone via well-defined six-membered ring 
transition state. 
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 Although both Me4N•BH(OAc)3 and Na•BH(OAc)3 were available, we chose the 
former to avoid any coordinating counter ions (such as Na+) that might interfere with the 
reaction. From a practical point of view, this reaction required -35°C to -40°C temperature 
overnight, a well-insulated bath equipped with a chiller was needed.  
Diol 20 was then converted to a cyclic carbonate 21, with N,N’-carbonyl diimidazole 
(CDI), a far safer alternative to phosgene (Scheme 17). Carbonate 21 was then treated 
with freshly prepared Cp2TiMe2 to give cyclic ketene acetal 17. We expected 17 to undergo 
[3,3]-sigmatropic rearrangement to afford desired 8-membered lactone in the same pot.  
 
Scheme 17. The synthesis of carbonate 11 and the sequential in situ generation of the ketene 
acetal 12 by Cp2TiMe2. 
 The Petasis reagent Cp2TiMe2 was freshly prepared by salt metathesis reaction 
between methylmagnesium bromide with titanocene dichloride (Cp2TiCl2). The reaction 
was clean and Cp2TiMe2 was quantified by quantitative 1HNMR.96 As an analog to Wittig 
reagents, Cp2TiMe2 can be used for methylenation of most types of neutral carbonyl 
functionalities including aldehydes, ketones, esters, anhydrides, carbonates, amides, 
imides, silyl esters, thioesters, selenoesters and acylsilanes, this robust reactivity is driven 
by Ti(IV)’s high oxophilicity.97–101 The mechanism of the olefination involves the formation 
of a carbene complex (Cp2Ti=CH2) via thermal a-elimination of Cp2TiMe2 (Scheme 18), 
which is followed by a [2+2] cycloaddition between the carbene and carbonyl group to 
afford an oxatitanacyclobutane intermediate, a sequential cyclo-reversion then delivers 
the cyclic ketene acetal 17 with the byproduct Cp2Ti=O. 
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Scheme 18. The mechanism for the methylenation of carbonyl compounds using Cp2TiMe2. 
 The ring expansion method via Claisen rearrangement from cyclic ketene acetal 
has been explored extensively by Holmes and co-workers.102–110 The transition state 
conformation analysis of the Claisen rearrangement provides an answer to why anti-diol 
configuration was needed in compound 20: if syn-20 was used, the resulting cyclic ketene 
acetal would have to adopt an unfavored 6-membered ring transition state with two 
substituents in axial positions (Scheme 19).  
 
Scheme 19. Transition states of cyclic ketene acetal during Claisen rearrangement. 
 Apart from the fact that 8-membered rings favor internal Z-double bonds instead of 
the E configuration, the proposed transition state in Scheme 19 also explains why the 
formation of Z-olefin is preferred to E-olefin from a kinetic point of view. Claisen 
rearrangement of 17 could either proceed through a chair-like or a boat-like transition state. 
The former would deliver a Z-olefin (compound 16) while the latter will give an E-
olefin102,104(Scheme 20). Molecules that could adopt both transition state geometries will 
prefer the chair-like geometry. This argument is supported by strong evidence from 
Paquette’s study on their Claisen-mediated formation of cyclooctenone.111 
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Scheme 20. The chair-like transition state during [3,3]-sigmatropic rearrangement explains the 
formation of Z-olefin. 
Unfortunately, the one-pot methylenation-Claisen rearrangement of 21 only yielded 
a trace amount of product 16. However, the 10-membered cyclic ketone 22 was formed 
as the major product. We reasoned that the desired product 16 was indeed formed, but in 
the presence of Cp2TiMe2, 16 quickly undergoes another methylenation-Claisen 
rearrangement sequence and thus results in cyclic ketone 22 (Scheme 21). 
 
Scheme 21. The formation of cyclic ketone 22. 
 The major product 22’s NMR data corresponds perfectly with the proposed 
structure. First of all, 13C-NMR shows a characteristic ketone carbonyl carbon peak at 
211.76 ppm. Secondly, it showed 11 carbon peaks, while the starting material 21 has 9 
distinct carbon atoms; this supports the conclusion that the methylenation occurred twice 
because every methylenation would add one more carbon to the molecule. Thirdly, DEPT-
135 showed that 22 has one quaternary carbon (C=O), 5 methine groups (-CH), 4 
methylene groups (-CH2) and 1 type of methyl groups (3 x -CH3 in -TMS group). Lastly, 
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1H-NMR suggests 4 alkenyl protons, 9 alkyl protons and 9 protons in the TMS group, 22 
protons in total. 
We concluded that Cp2TiMe2 was too reactive, and desired product 16 was likely 
more reactive than starting material 21 towards Cp2TiMe2, thus the reaction cannot stop 
at 16 under the reaction conditions.  
 
2.3 Third Synthetic Approach Towards Fragment 3 
 To overcome the over methylenation issue in the previous attempt, we devised 
another method to access the Claisen rearrangement precursor 17, it features the double 
bond formations via selenoxide elimination instead of Cp2TiMe2.  
 Anti-diol 32 was synthesized by the similar reaction sequence that led to Anti-diol 
20 (Scheme 22, B) with the main difference being the aldol reaction. The aldol starting 
materials 26 and 30 were designed so that MVK was not involved. Therefore b-hydroxyl 
ketone 31 was formed with a much better yield than 19. Also, aldehyde 26 was 
synthesized as the electrophile in the aldol reaction (Scheme 22, A), as here it served as 
an acrolein equivalent, acrolein being difficult to handle and thus should be avoided. 
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Scheme 22. The syntheses of aldehyde 26 and anti-diol 32. 
 Acetal 35 was first synthesized quantitatively from electrophilic phenylselenyl 
chloride and ethyl vinyl ether in ethanol (Scheme 23, A). 35 serves as an acetal transfer 
reagent for the acetalization of diol 23 under acidic condition, furnishing cyclic acetal 36. 
Since we designed 36 to contain two phenylselenide functionalities, upon treatment of a 
suitable oxidizing agent such as NaIO4, we envisioned both phenylselenides should be 
oxidized to selenoxide, and then undergo fast thermal syn-elimination to deliver cyclic 
ketene acetal 17.112 In the same pot, we envisioned 17 would undergo a sequential 
Claisen rearrangement and deliver the desired lactone 16 (Scheme 23, B).102–104,107,109  
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Scheme 23. The proposed alternative synthesis of lactone 8. 
 However, after 36 was treated with the oxidation-Claisen sequence, no desired 
product 16 was observed. Only one selenide group underwent oxidation to give the only 
product 38 (Figure 6), even with a superstoichiometric amount of oxidant and elevated 
temperature.  
 
Figure 6. The only product 38 observed after treating 36 with oxidation-Claisen conditions 
described in Scheme 23, B. 
 The incompetent selenium oxidation under similar reaction conditions was also 
witnessed by Holmes and co-workers.104,105 Perhaps it can be explained by the 
disproportionation of the elimination byproduct benzeneselenenic acid (40, PhSe-OH) 
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under the reaction condition (Scheme 24).105 Assuming Se1 undergoes b-elimination 
faster than Se2, the selenoxide elimination byproduct, benzeneselenenic acid 40, has 
been shown to disproportionate to benzeneseleninic acid 41 and diphenyl diselenide 42. 
The latter can be a reducing agent and is hypothesized to transform selenoxide 39 back 
to 38. 
 
Scheme 24. Selenoxide 41 can be reduced back to selenide 39 because of the 
disproportionation of benzeneselenenic acid 41. 
 Before exploring more reaction conditions to overcome the selenide oxidation 
problem, some other concerns about this olefination-Claisen method surfaced. First of all, 
ketene acetal intermediate 17 has two vinyl substituents branching off the ring, both of 
them could potentially undergo Claisen rearrangement with the ketene acetal group, 
although we anticipate the mono-substituted olefin to be more reactive. The same Claisen 
rearrangement with a vinyl silane (-SiMe2Ph) also has been reported before.110  
 Our second concern was the iodination reaction from vinyl silane 16 to vinyl iodide 
3 (Scheme 10). We performed many experiments to test the feasibility of the iodination 
with substrates similar to 16 (Scheme 25). After extensive experimentation, we failed to 
iodinate ester 15 as the reactions gave inseparable mixtures of products, and the best 
yield obtained with alcohol 13 was only 25%.  
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Scheme 25. Results of the desilyliodination reactions of 15 and 13. 
 Facing these difficulties and limitations we experienced for the synthesis of vinyl 
iodide lactone 3, we decided to start exploring the synthesis of 4. The synthesis of 4 was 
also designed to bypass the problematic or low-yielding reactions we learned during the 
synthesis of 3, such as the aldol condensation involving MVK and the desilyliodination 
reaction.  
 
2.4 Synthetic Approach to Fragment 4  
 The synthesis of 4 can be accomplished by a Wittig reaction between aldehyde 43 
and phosphonium ylide 44 (Scheme 26). Luckily, 44 is an unstabilized ylide which is 
required for the formation of Z-olefin. Although 43 seems to be a simple molecule, it 
contains a b-hydroxyl aldehyde, which is usually inaccessible by classic aldol. Moreover, 
in this case, the aldol reaction to form 43 would require an acetaldehyde that is particularly 
problematic because of its self-condensation. Alternatively, a Stork reaction could be 
employed to tackle this issue. However, the corresponding enamine from acetaldehyde is 
sensitive and requires distillation to purify, which is challenging without a proper setup. 
 
Scheme 26. Retrosynthetic analysis of 4. 
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 Therefore, we designed a synthesis of 43 that does not involve aldol-type reactions. 
Commercially available acetylene 45 was formylated with DMF to give aldehyde 46 in 
quantitative yield (Scheme 27). Aldehyde 46 was then treated with Grignard reagent 47 
to deliver alcohol 48. This reaction was performed at 60°C in THF. The high temperature 
required is unconventional for Grignard reactions. The acetylenic TIPS group was then 
removed by TBAF to give acetal 49. Compound 49 is a masked b-hydroxyl aldehyde, the 
acetal group will be eventually removed to reveal the aldehyde, thus we decided to protect 
the -OH group with an acid-robust silyl group (TBDPS) and arrived at acetal 50. Otherwise 
under the deacetalization conditions, the unprotected -OH tends to be eliminated and give 
exclusively the conjugated aldehyde, a problem we experienced in some early test 
experiments for acetal hydrolysis  
 
Scheme 27. The synthesis of 50. 
The significance of zirconocene hydrochloride (HCp2ZrCl) in organic synthesis is 
well-established,113–117 including in hydrozirconation or halogenation of alkenes and 
alkynes,118,119 reductions of various organic functional groups such as amides and 
oxazolidinones (Evans’ auxiliary),118,120 as well as application in transition metal-catalyzed 
coupling reactions.119 However, HCp2ZrCl suffers from a short shelf life due to its unstable 
nature. Therefore a number of efforts have been made to generate it in situ, which largely 
involves treating zirconocene dichloride (Cp2ZrCl2) with a reducing agent such as a metal 
hydride118,119 or an alkylmagnesium bromide.121 
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Alkyne 50 was treated first with HCp2ZrCl generated in situ from Cp2ZrCl2 and 
DIBAL-H, then the reaction was quenched with I2 to furnish vinyl iodide 51 (Scheme 
28).119 The trans double bond geometry was confirmed by the large coupling constant 
between the two alkenyl protons (3JHH = 14.44 Hz). The aldehyde group in 52 was then 
revealed by hydrolyzing the acetal with a mild Lewis acid PdCl2(MeCN)2. 
 
Scheme 28. The synthesis of aldehyde 52. 
The hydrozirconation of an alkyne with HCp2ZrCl is stereospecific, cis addition of 
Zr-H across the triple bond is almost always observed,122 giving two possible vinyl 
zirconium intermediates 53 or 54 (Scheme 29). However, the zirconocene moiety is bulky 
and thus sensitive to steric congestion. It would preferably position itself away from the 
larger vinyl substituent, making 53 the dominant intermediate. Upon quenching 53 with I2, 
a vinyl iodide 51 with E configuration was formed. In the last iodination step, the 
mechanism could be a direct electrophilic attack of the -ZrCp2Cl moiety, or a s-bond 
metathesis, since an oxidative insertion pathway was impossible for an electropositive, d0 
metal center. 
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Scheme 29. Regioselectivity of the iodination of 50 via vinyl zirconium intermediate. 
Before using PdCl2(MeCN)2, several methods to hydrolyze the acetal group in 51 
were examined. When simple Bronsted acids were used, the hydrolysis was extremely 
slow, with very low conversion even after prolonged reaction time. Lewis acid-catalyzed 
transacetalization seemed to be more suitable in this case, with 10% PdCl2(MeCN)2 and 
a large excess of acetone, aldehyde 52 was obtained in 49% yield, the rest was almost 
all recovered 51. It is worth mentioning that the much stronger Lewis acid FeCl3 also gave 
a similar yield in much shorter reaction time, but no acetal 51 could be recovered due to 
other side reactions.  
The desired compound 4 was synthesized by a Wittig reaction between the 
unstabilized phosphonium ylide 44 and aldehyde 52 in 58% yield (Scheme 30). To ensure 
its Z-olefin selectivity, the reaction temperature was strictly controlled below -78°C. 
 
Scheme 30. The synthesis of fragment 4. 
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pathways,124 [2+2] cycloaddition pathways,125,126 single electron transfer pathway127, etc. 
Also, the mechanism is likely to change with the reaction conditions and the reactants 
involved. Nevertheless, the formation of an oxaphosphetane intermediate during Wittig 
reaction is generally accepted. Under kinetic control in the transition state (TS) of the 
oxaphosphetane intermediate formation (Scheme 31), R2 is positioned away from R1 and 
the bulky triphenylphosphonium group to minimize steric interaction. The resulting 
oxaphosphetane intermediate would have two R groups in a syn relationship, which would 
naturally produce Z-olefin upon oxaphosphetane decomposition, with triphenylphosphine 
oxide as a byproduct, the thermodynamic driving force. 
 
Scheme 31. The mechanism and stereoselectivity of Wittig reaction using non-stabilized 
phosphonium ylide. 
The two alkenyl protons (H-4 and H-5) in product 4 gave an overlapping and 
complex multiplet on the 1HNMR spectrum, thus their coupling constants cannot be 
extracted directly to confirm the double bond geometry. Fortunately, H-4 and H-5’s six 
neighboring protons (H-2, H-3, H-6) also appeared together between 2.1 to 2.2 ppm, ideal 
for a homo-decoupling NMR experiment (spectra: page 89). In the decoupled 1H-NMR 
spectrum of 4, H-4 appeared as a doublet and H-5 became a doublet of doublets (H-5 is 
4JHH coupled to H-7). The vicinal 3JHH between H-4 and H-5 can be determined to be 10.7 
Hz, which falls into the range of typical 3JHH of two cis alkenyl protons (10-12 Hz).128 
Furthermore, the 3JHH of two alkenyl protons is 15.09 Hz in trans-2-butene, and 10.88 Hz 
in cis-2-butene,129 with the latter is very close to that of 4 (Scheme 32). 
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Scheme 32. The confirmation of the double bond geometry between C4 and C5 via H-H 
coupling constant. 
 
2.5 Synthetic Approach to Fragment 5 
 Commercially available alcohol 55 was converted to the corresponding tosylate 56 
by treating with tosyl chloride (Scheme 33).130 The Cu-mediated coupling reaction 
between 56 and propargyl alcohol afforded alcohol octa-2,5-diyn-1-ol 57 in good yield.131 
The -OH group in 57 was then converted to a bromide (58) by an Appel reaction using 
triphenylphosphine and CBr4. In the Appel reaction, CBr4 can be substituted with Br2 and 
result in the formation of 58 with the same yield. Next, the direct propargylic substitution 
of 58 with commercially available skipped diyne 59, under the same CuI-mediated 
conditions, gave TMS-protected skipped tetrayne 60. The skipped tetrayne 60 is unstable 
and decomposes quickly during flash column chromatography. However, the crude 
product was very clean judging by its NMR, therefore the crude 60 was carried to the next 
step without further purification.  
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Scheme 33. The synthesis of skipped tetrayne 60. 
 The copper-mediated substitution of propargylic halide or tosylate by terminal 
alkynes provides a mild way to quickly assemble skipped poly-yne systems. This method 
was described almost at the same time by Jeffery,132 Pivnitsky,133 and Huang.134 The 
reaction mechanism is generally accepted to be an SN2 mechanism (Scheme 34).  The 
acetylenic proton on the terminal alkyne is significantly acidified by the coordination of Cul 
to the triple bond. After deprotonation, a copper(l) acetylide nucleophile is produced. In 
comparison, other methods usually involve the use of a strong base to create the 
acetylenic nucleophile, and the resulting highly basic and nucleophilic conditions are 
obliviously incompatible with many sensitive functional groups.  
 
Scheme 34. The mechanism for the Cul-mediated propargylic substitution of a leaving group by 
a terminal alkyne. 
The selective semi-hydrogenation of 60 to 61 was more challenging than expected. 
Initially attempts using Lindlar catalyst with 1.1 equivalents of quinoline additive under H2 
atmosphere failed. Varying the temperature, solvent and catalyst loading, the amount of 
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quinoline and the H2 pressure did not lead to any improvement. The Rosenmund catalyst 
(Pd on BaSO4) also failed to give any conversion under various conditions (Scheme 35). 
Although the hydrogenation of alkynes seems like a trivial matter and it was perceived as 
such in most student books, a literature survey suggests that the semi-reduction of 
alkynes becomes challenging in poly-yne systems. Especially when other functional 
groups are present, semi-hydrogenation reactions are usually highly dependent on 
conditions.135 In some unfortunate cases, several alkyne substrates simply do not undergo 
hydrogenation using Lindlar or other Pd-based catalysts.136  
 Luckily there are many semi-hydrogenation methods in the chemist’s toolbox. We 
decided to employ the P2-Ni heterogenous catalyst, although it was less practical 
compared to Lindlar or Rosenmund. During World War II, Brown and Schlesinger 
observed granular black precipitates when some first-row metal salts (cobalt, iron, nickel 
or copper) were treated with sodium borohydride. In aqueous media, they found out that 
when nickel acetate was treated with sodium borohydride, the resulting fine black power 
can be used to reduce olefins. Later this system was termed P1-Nickel. Subsequently, 
after extensive experimentations, a derivative of the P1-Nickel system was finally 
discovered to semi-hydrogenate alkynes to cis-alkenes, with excellent stereo- and 
chemoselectivity. This novel catalytic system was referred to as P2-Nickel, made under 
standardized conditions that include the use of Ni(OAc)2, ethylenediamine as catalyst 
modifier and ethanol as solvent.  
Even though the P2-Ni catalyst is extremely sensitive to oxygen and cannot be 
stored, it has emerged as one of the most used reducing reagents for the semi-
hydrogenation of alkynes, probably only second to Lindlar catalyst, because of its mild 
reaction condition and extremely wide functional group compatibility. In our hands, the 
semi-hydrogenation of tetrayne 60 using P2-Ni catalyst provided 61 in 26% yield despite 
our best efforts (Scheme 35). It is worth noting that 60 was subjected to hydrogenation 
reaction as a crude product. Thus an impurity might have hampered the hydrogenation 
reaction. Lastly, the trimethylsilyl group was cleaved in K2CO3/methanol to furnish 
fragment 5. 
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Scheme 35. Synthesis of S3 via P2-Ni-catalyzed poly yne semi-hydrogenation. 
 
2.6 Completion of the Synthesis of (±) 7-HDHA 
With the fragment vinyl iodide 4 and terminal alkyne 5 in hand, we were ready to 
join these two pieces and complete the synthesis of our final target (±) 7-HDHA in a few 
more steps. Firstly, the complete carbon assembly of 7-HDHA can be furnished by a 
Sonogashira reaction between 4 and 5.  
The Sonogashira coupling is a palladium-catalyzed C-C bond forming reaction that 
couples a terminal sp-hybridized carbon atom with an sp2 carbon atom of a vinyl or aryl 
halide or pseudo-halide. Since its development in 1975 by Sonogashira,137 it has become 
one of the most robust ways to construct C-C bonds. A report in 2011 concluded that in 
medicinal chemistry, in terms of C-C formation, the Sonogashira reaction was the second 
most used reaction in the pursuit of drug candidates.138 The mechanism of the 
Sonogashira reaction is generally believed to involve two independent catalytic cycles 
(Scheme 36). While the palladium cycle follows a classic mechanism of a palladium-
catalyzed coupling reaction. The exact mechanism of the copper cycle is still poorly 
understood.139 It is believed that the Cul species coordinates to the terminal alkyne to give 
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a p-alkyne copper complex, that significantly increases the acidity of the acetylenic proton. 
A weak base is then able to remove the acetylenic proton and give a neutral copper 
acetylide, which can be transferred to the palladium cycle via transmetalation.140 
 
Scheme 36. The catalytic mechanism of Sonogashira coupling reaction. 
The Sonogashira coupling reaction between 4 and 5 was very smooth (Scheme 
37) and gave compound 2 (96%) as a 7-HDHA derivative.  
 
Scheme 37.The synthesis of 2 by Sonogashira coupling reaction. 
  The next step would be a cis semi-hydrogenation of 2 to furnish the final Z-double 
bond in the molecule between C10 and C11. The method needed to be very mild to avoid 
any possibilities of double bond isomerization. A survey of the literature confirmed some 
of our concerns associated with popular Pd-based catalysts. For example, Batista-Pereira 
and co-workers experienced an unexpected isomerization of a conjugated Z-double bond 
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to its more stable E configuration when Lindlar’s catalyst was used (Scheme 38, A).141 In 
the synthesis of lipoxin A4 (Scheme 38, B), Nicolaou and co-workers also reported the 
isomerization of the desired (7E,9E,11Z,13E)-tetraene to its more stable all-trans isomer 
during Lindlar semi-hydrogenation (DCM, r.t., quinoline). Although the isomerization only 
occurred to a small extent, the purification of the product tetraene was hampered, and 
ultimately required reverse-phase HPLC separation.142 In another report that examed a 
series Pd-based semi-hydrogenation catalysts, the authors concluded that the extent of 
this cis-trans stereomutation was unpredictable.143  
 
Scheme 38. Two examples of double bonds undergoing cis-trans isomerization under semi-
hydrogenation using Lindlar catalyst. 
 With the concerns of olefin cis-trans isomerization and the consequential 
problematic separation, we decided to steer away from Pd-based semi-hydrogenation 
methods. During our literature search, a heterogeneous semi-hydrogenation method that 
uses a mixture of Zn(0), Cu(OAc)2, and AgNO3 reagents came to light. The Zn(Cu/Ag) 
semi-hydrogenation protocol was reported by Boland and co-workers144 in the 1980s. In 
essence, this Zn-based semi-hydrogenation method features very mild reaction conditions, 
high reproducibility, excellent Z-selectivity, and fortunately in our favour, it is only reactive 
towards conjugated C-C triple bonds like the one in substrate 2.  
 Initially, we followed the same reaction conditions as Boland and co-workers 
reported but always arrived at an incomplete conversion. Although no side product was 
formed, the separation of 1 and 2 was very difficult by flash column chromatography. To 
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achieve the full conversion of 2, we first realized that the reaction solvent (water or 
methanol) cannot dissolve 2, which made the introduction of a small amount of 2 into the 
reaction mixture impossible. Fortunately, one report used dioxane/water mixture as the 
reaction solvent and obtained a good yield and Z-selectivity.145 Thus a solution of 2 in 
dioxane was prepared and efficiently transferred to the Zn(Cu/Ag) mixture. Secondly, the 
conversion increased when zinc dust was freshly activated by 1M HCl before use. Lastly 
and most importantly, we found that after the reaction stalled, spiking the reaction mixture 
with a few drops of aqueous 1M HCl can promote the reaction further to some extent.145 
The addition of small amounts of 1M HCl every 24 hours eventually pushed the reaction 
to completion in two days, and furnished 1 in quantitative yield (Scheme 39). 
 
Scheme 39. The synthesis of 1. 
 In the 1H-NMR spectrum of product 1, the signals of H-8, H-9, and H-10 were well 
resolved, however, H-11’s peak completely overlaps with the other alkenyl protons. The 
H-10 signal was a doublet of doublets with coupling constants of 10.82 Hz and 10.82 Hz 
(apparent triplet), which falls into the range of typical 3JHH of two cis alkenyl protons. On 
the other hand, the trans-3JHH between H-8 and H-9 was 15.11 Hz.  
To complete the synthesis of (±) 7-HDHA, the TBDPS protecting group in 1 was 
removed with TBAF to reveal the alcohol 62 with 78% yield (Scheme 40). Next, the ester 
group in 62 was converted to a carboxylic acid group under ester hydrolysis condition 
(LiOH in THF/H2O), delivering the final target (±) 7-HDHA in 80% yield.  
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Scheme 40. Completion of the synthesis of (±) 7-HDHA. 
 To our best knowledge, there is no reported NMR data for (±) 7-HDHA in the 
literature. Thus, we acquired a collection of 1D and 2D NMR spectra from a 700 MHz 
NMR spectrometer, to confirm the structure of our synthesized (±) 7-HDHA. Using 2D 
COSY, 2D TOCSY, 2D HSQC, 2D HMBC, 2D HSQC-TOCSY, and 2D-HSQC-DEPT 
spectra, the connectivity of atoms of (±) 7-HDHA was proven, and all the carbon and 
proton signals were assigned. The cis-geometry of the double bonds can be confirmed by 
the 2D-NOESY spectrum, as the allylic protons on the opposite sites of a cis double bond 
show NOESY correlation. 
 
Figure 7. NOESY correlations are used to confirm the double bonds’ cis-geometry. 
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3. Conclusion 
 In conclusion, convergent total synthesis of (±) 7-HDHA was completed with the 
longest linear reaction sequence of 11 steps from commercially available 
(triisopropylsilyl)acetylene. The overall yield of the final product is 12% (calculated based 
on the longest linear reaction sequence). This concise route mainly relies on the 
simultaneous formation of multiple Z-double bonds with the semi-hydrogenation catalyst 
P2-Nickel, and a late-stage semi-hydrogenation with Zn(Cu/Ag) reagent. Using this route, 
large quantities of (±) 7-HDHA were prepared rapidly with high quality (compared to 
commercial supply), and we are able to supply our collaborator generously. As a result, 
more comprehensive studies on (±) 7-HDHA in relations to PPAR nuclear receptors were 
initiated. Moreover, this synthetic route paved the way for the syntheses of enantiopure 
(+) 7-HDHA and (-) 7-HDHA that are currently in progress.  
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4. Experimental Section 
4.1 General Experimental 
 All reactions were conducted in flame- or oven-dried glassware under an 
atmosphere of argon unless specified otherwise. All solvents were freshly distilled or 
obtained from solvent purification system (InertÒ PureSolv MD5) prior to use unless 
specified otherwise. Triethylamine and diisopropylamine were distilled from CaH2. 
Commercial reagents were used as received. Thin-layer chromatography was performed 
on SiliCycleÒ silica gel 60 F254 plates. Visualization was carried out using UV light (254 
nm) and/or KMnO4, (NH4)2Ce(NO3)6, vanillin, or anisaldehyde solution. Hexanes (ACS 
grade) and ethyl acetate (ACS grade) were used as received. Flash column 
chromatography was carried out using SiliCycleÒ SiliaFlashÒ silica gel (230-400 mesh, 40-
63 µm, 60 Å pore size). All NMR spectra were recorded on a Bruker 300 AV, Bruker 400 
AV, Bruker DRX 600 or Bruker Ascend 700 spectrometer in chloroform-d (99.8% 
deuterated), using TMS in chloroform-d as an external standard. Spectral recorded using 
chloroform were calibrated to 7.26 ppm 1H and 77.16 ppm 13C. Chemical shifts (d) are 
reported in ppm and multiplicities are indicated by s (singlet), d (doublet), t (triplet), q 
(quartet), p (pentet), sext (sextet), td (triplet of doublets), dd (doublet of doublets), dddd 
(doublet of doublet of doublet of doublets), m (multiplet), or br (broad). Coupling constants 
J are reported in Hertz (Hz).  
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4.2 Experimental Procedures of the Synthesis of (+) 7-HDHA: Final Route 
3-(triisopropylsilyl)propiolaldehyde (46) 
 
 An oven-dried 200 mL round-bottom flask was filled with argon, and charged with 
a magnetic stirring bar and A (45, 5.00 g, 27.42 mmol, 1.0 equiv.) in 30 mL dry Et2O. The 
solution was cooled to 0°C, n-BuLi (1.6 M in hexane, 18.85 mL, 30.16 mmol, 1.1 equiv.) 
was added dropwise to the flask at 0°C, and the reaction was stirred at 0°C for 30 min. 
DMF in 20 mL Et2O was then added dropwise to the reaction mixture at 0°C. The reaction 
mixture was stirred at 0°C for 2 hours and was then quenched at 0°C by slow addition of 
1M HCl until a slightly acidic pH was reached. After 1 hour of stirring at room temperature. 
the organic phase was separated, and the aqueous phase was extracted exhaustively 
with ether. The organic layers were combined, washed over brine and dried over MgSO4, 
filtered and concentrated under reduced pressure. The residual oil was purified by flash 
chromatography using ethyl acetate and hexane (10:90) as eluent to afford 1-
(triisopropylsilyl)-1-propynal (46) as a pale-yellow oil (5.73 g, 99% yield). The 1H-NMR and 
13C-NMR data is in accordance with that previously reported in the literature.146 
1H-NMR  (400 MHz, CDCl3), see page 74 
δ 9.21 (s, 1H), 1.13-1.09 (m, 21H) 
13C-NMR  (100 MHz, CDCl3), see page 75 
δ 176.80, 104.60, 101.06, 18.55, 11.08 
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1-(1,3-dioxolan-2-yl)-4-(triisopropylsilyl)but-3-yn-2-ol (48) 
 
An oven-dried 200 mL round-bottom flask was filled with argon, charged with a 
magnetic stirring bar and equipped with a condenser. B (458.47 mg, 19.00 mmol, 4 equiv.) 
and 20 mL THF was first added to the flask, followed by the addition of A (1.59 g, 9.5 
mmol, 2 equiv.) and a crystal of I2. The reaction mixture was stirred for 2 hours at room 
temperature, then D (1.0 g, 4.75 mmol, 1 equiv.) in 5 mL THF was added dropwise to the 
Grignard reagent. The reaction mixture was stirred at room temperature overnight, and 
then cooled to 0°C. 20 mL of water was added to the reaction, which was followed by the 
addition of saturated aqua. NH4Cl. The organic phase was separated, and the aqueous 
phase was extracted with ether (X3). The organic layers were combined, washed over 
brine and dried over MgSO4, filtered and concentrated under reduced pressure. The 
residual oil was purified by flash chromatography using ethyl acetate and hexane (30:70) 
as eluent to afford 48 as a colorless oil (1.18 g, 83% yield). 
1H-NMR (300 MHz, CDCl3), see page 76 
δ 5.17 (dd, J = 5.43 Hz, 4.41 Hz, 1H), 4.66 (m, 1H), 4.03-3.86 (m, 4H), 2.89 
(d, J = 4.89 Hz, 1H), 2.21-2.02 (m, 2H), 1.07-1.05 (m, 20H) 
13C-NMR (75 MHz, CDCl3), see page 77 
δ 107.61, 102.68, 85.82, 64.98, 59.58, 41.15, 18.68, 11.21 
HRMS (EI) mass [M+NH4+]+ calculated: 316.23025 Da; found: 316.23107 Da 
 
  
OH
TIPS
O
O
O
O
Br
83%
THF, r.t.
C 47 48
O
TIPS
H
D. 46 (1.0 equiv.)A. 2 equiv.
B. Mg (4 equiv.)
O
O
BrMg
THF, r.t.+
 48 
1-(1,3-dioxolan-2-yl)but-3-yn-2-ol (49) 
 
A 50 mL round-bottom flask was charged with a magnetic stirring bar, and A (500.0 
mg, 1.68 mmol, 1 equiv.) in 20 mL THF. B (483.3 mg, 1.85 mmol, 1.1 equiv.) was added 
to the reaction mixture portion-wise. The mixture was stirred at room temperature for 3 
hours. Next, the reaction mixture was concentrated using a rotary evaporator. The 
residual mixture was dissolved in ethyl acetate. This organic phase was then washed over 
brine, and dried over MgSO4, filtered and concentrated under reduced pressure. The 
residual oil was purified by flash chromatography using ethyl acetate and hexane (50:50) 
as eluent to afford 49 as a colorless oil (217.13 mg, 83% yield). The 1H-NMR and 13C-
NMR data is in accordance with that previously reported in the literature.147 
1H-NMR (300 MHz, CDCl3), see page 78 
δ 5.16 (dd, J =4.86 Hz, 4.68 Hz, 1H), 4.67 (m, 1H), 4.05-3.87 (m, 4H), 3.07 
(d, J = 5.34 Hz, 1H), 2.48 (d, J = 2.22 Hz, 1H), 2.22-2.04 (m, 2H) 
13C-NMR (75 MHz, CDCl3), see page 79 
δ 102.53, 83.86, 73.17, 65.03, 58.86, 40.52 
 
  
B. TBAF (1.1 equiv.)OH
TIPS
O
O
THF, r.t.
A. 48 (1 equiv.)
OH
H
O
O
91%49
 49 
((1-(1,3-dioxolan-2-yl)but-3-yn-2-yl)oxy)(tert-butyl)diphenylsilane (50) 
 
A 25 mL round-bottom flask was charged with a magnetic stirring bar and filled with 
argon. 5 mL of DMF was added to the flask, followed by the addition of A (214.00 mg, 
1.51 mmol, 1 equiv.) and C (257.34 mg, 3.78 mmol, 2.5 equiv.). B (496.23 mg, 1.81 mmol, 
1.2 equiv.) in 2 mL of DMF was added to the reaction mixture dropwise at room 
temperature. the reaction was stirred overnight. Next, the mixture was diluted with Et2O, 
and water was added. The organic phase was separated, and the aqueous phase was 
extracted with ether (X3). The organic layers were combined, washed over brine and dried 
over MgSO4, filtered and concentrated under reduced pressure. The residual oil was 
purified by flash chromatography using ethyl acetate and hexane (20:80) as eluent to 
afford 50 as a colorless oil (570.20 mg, 99% yield). 
1H-NMR (600 MHz, CDCl3), see page 80 
δ 7.75 (d, J = 6.72 Hz, 2H), 7.70 (d, J = 7.35 Hz, 2H), 7.44-7.36 (m, 6H), 
5.02 (t, J = 5.1 Hz, 1H), 4.57 (td, J = 6.78 Hz, 1.92 Hz, 1H), 3.88-3.74 (m, 
4H), 2.32 (d, J = 1.92 Hz, 1H), 2.10-2.03 (m, 2H), 1.08 (s, 9H) 
13C-NMR (150 MHz, CDCl3), see page 81 
δ 136.22, 136.06, 133.53, 129.89, 129.80, 127.72, 127.53, 101.77, 84.34, 
73.55, 64.87, 64.76, 60.740, 42.94, 27.03, 19.44 
HRMS (EI) mass [M+H+]+ calculated: 381.18805 Da; found: 381.18857 Da  
OH
H
O
O O
H
O
O
TBDPS
quantitative
B. TBDPS-Cl (1.2 equiv.)
C. imidazole (2.5 equiv.)
DMF, r.t.
A. 49 (1.0 equiv.) 50
 50 
(E)-((1-(1,3-dioxolan-2-yl)-4-iodobut-3-en-2-yl)oxy)(tert-butyl)diphenylsilane (51) 
 
A 25 mL round-bottom oven-dried flask was charged with a magnetic stirring bar 
and filled with argon. In the flask, B (602.16 mg, 2.06 mmol, 2.0 equiv.) was dissolved in 
2.5 mL of THF, and the solution was cooled to 0°C. DIBAL-H (1.0 M in toluene, 1.85 mL, 
1.85 mmol, 1.8 equiv.) was added dropwise into the reaction flask. The reaction was left 
stirring for 30 minutes. A (392.2 mg, 1.03 mmol, 1 equiv.) in 1.5 mL of THF was added 
dropwise to the reaction mixture at 0°C. After 1 hour of stirring, the reaction was cooled 
to -78°C, and D (522.85 mg, 2.06 mmol, 2.0 equiv.) in 1.5 mL of THF was added dropwise 
(very slowly) to the reaction mixture. After 20 minutes stirring, the reaction was quench 
with 1 M HCl. The organic phase was separated, and the aqueous phase was extracted 
with ether (X3). The organic layers were combined, washed successively with saturated 
Na2S2O3, NaHCO3 and brine, dried over MgSO4, filtered and concentrated under reduced 
pressure. The residual oil was purified by flash chromatography using ethyl acetate and 
hexane (5:95) as eluent to afford 51 as a colorless oil (485.5 mg, 93% yield). 
1H-NMR (400 MHz, CDCl3), see page 82 
δ 7.66-7.61 (m, 4H), 7.43-7.36 (m, 6), 6.48 (dd, J = 14.44 Hz, 7.40 Hz, 1H), 
5.88 (dd, J =14.24 Hz, 0.84 Hz, 1H), 4.87 (t, J = 5.16 Hz, 1H), 4.31 (q, J = 
6.56 Hz, 1H), 3.87-3.72 (m, 4H), 1.92 (m, 1H), 1.80 (m, 1H), 1.05 (s, 9H) 
13C-NMR (100 MHz, CDCl3), see page 83 
δ 147.58, 135.94, 133.57, 129.76, 127.59, 101.53, 77.89, 73.01, 64.69, 
64.64, 41.69, 26.99, 19.37 
HRMS (EI) mass [M+Na+]+ calculated: 531.0823 Da; found: 531.0816 Da  
O
H
O
O
TBDPS
A. 50 (1.0 equiv.)
1. B. Cp2ZrCl2 (2.0 equiv.)
C. DIBAL-H (1.8 equiv.)
THF, 0℃
2. D. I2 (2.0 equiv.), -78℃
O
I O
O
93%51
TBDPS
 51 
 
(E)-3-((tert-butyldiphenylsilyl)oxy)-5-iodopent-4-enal (52) 
 
 A 50 mL round-bottom flask was charged with a magnetic stirring bar, filled with 
argon and added 20 mL of acetone. A (50.00 mg, 0.1 mmol, 1.0 equiv.) was added to the 
flask, which was followed by the addition of B (2.60 mg, 0.01 mmol, 0.1 equiv.). the 
reaction mixture was stirred at room temperature, in the dark for two days. The solvent 
was then removed, and the residual mixture was dissolved in Et2O, dried over MgSO4, 
filtered and concentrated under reduced pressure. The residual oil was purified by flash 
chromatography using hexane and toluene (10:90) as eluent to afford 52 as a colorless 
oil (22.75 mg, 49% yield). 
1H-NMR (300 MHz, CDCl3), see page 84 
δ 9.67 (t, J = 2.19 Hz, 1H), 7.65-7.60 (m, 4H), 7.45-7.37 (m, 6H), 6.54 (dd, 
J = 14.48 Hz, 6.57 Hz, 1H), 6.12 (dd, J = 14.46 Hz, 0.99 Hz, 1H), 4.58 (q, J 
= 5.73 Hz, 1H), 2.59-2.44 (m, 2H), 1.05 (s, 9H) 
13C-NMR (176 MHz, CDCl3), see page 85 
δ 200.34, 146.45, 135.96, 133.07, 130.21, 127.93, 78.74, 71.77, 50.41, 
27.04, 19.42 
HRMS (EI) mass [M+NH4+]+ calculated: 482.10068 Da; found: 482.10053 Da  
 
  
O O
I H
49%
B. PdCl2(MeCN)2 (10mol%)
acetone
52
TBDPS
O
I O
O
TBDPS
A. 51 (1.0 equiv.)
 52 
(4Z,8E)-ethyl 7-((tert-butyldiphenylsilyl)oxy)-9-iodonona-4,8-dienoate (4) 
 
A 25 mL round-bottom oven-dried flask was charged with a magnetic stirring bar 
and filled with argon. B (667.73 mg, 1.46 mmol, 4.3 equiv.) in 3 mL of THF was introduced 
into the flask, which was then cooled to -78°C. C (0.5 M in toluene, 2.72 mL, 1.36 mmol, 
4.0 equiv.) was added dropwise into the flask, a yellow suspension was resulted. After 1 
hour of stirring at -78°C. A (106 mg, 0.34 mmol, 1.0 equiv.) in 3 mL of THF was added 
dropwise (very slowly) to the reaction mixture. After 1 hour stirring at -78°C, the reaction 
was quenched by saturated NH3Cl, and diluted with Et2O. The organic phase was 
separated, and the aqueous phase was extracted with ether (X3). The organic layers were 
combined, washed with brine, dried over MgSO4, filtered and concentrated under reduced 
pressure. The residual oil was purified by flash chromatography using ethyl acetate and 
hexane (5:95) as eluent to afford 4 as a colorless oil (110.84 mg, 58% yield). 
1H-NMR (400 MHz, CDCl3), see page 86 
δ 7.67-7.61 (m, 4H), 7.44-7.35 (m, 6H), 6.47 (dd, J = 14.40 Hz, 6.56 Hz, 1H), 
5.98 (dd, J = 14.40 Hz, 1.04 Hz, 1H), 5.42-5.28 (m, 2H), 4.14-4.08 (m, 3H), 
2.28-2.16 (m, 6H), 1.25 (t, J = 7.12 Hz, 3H), 1.06 (s, 9H) 
13C-NMR (100 MHz, CDCl3), see page 87 
δ 173.17, 147.86, 136.01, 133.89, 133.58, 130.39, 129.92, 127.75, 125.44, 
75.70, 60.46, 35.25, 34.27, 27.12, 22.99, 19.46, 14.01 
HRMS (EI) mass [M+NH4+]+ calculated: 580.17384 Da; found: 580.17322 Da  
 
 
PPh3
O
OEt
C. KHMDS (4.0 equiv.) 
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O
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O
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O O
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A. 52 (1.0 equiv.)
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 53 
pent-2-yn-1-yl 4-methylbenzenesulfonate (56) 
 
 In a 100 mL round-bottom flask, A (1.00 g, 11.89 mmol, 1.0 equiv.) was dissolved 
in 25 mL Et2O. B (2.83 g, 14.86 mmol, 1.25 equiv.) and C (3.34 g, 59.45 mmol, 5.0 equiv.) 
were added into the solution. after the mixture was stirred at room temperature overnight, 
20 mL Et2O was added. The reaction mixture was washed with saturated NaHCO3, brine, 
dried over MgSO4, filtered and concentrated under reduced pressure to afford 4 as a pale 
yellow oil (2.51 g, 89% yield), no further purification was needed. The 1H-NMR and 13C-
NMR data is in accordance with that previously reported in the literature.131 
1H-NMR  (400 MHz, CDCl3), see page 89 
δ 7.82 (d, J = 8.28 Hz, 2H), 7.34 (d, J = 8.22 Hz, 2H), 4.70 (t, J = 2.16 
Hz, 2H), 2.45 (s, 3H), 2.12-2.06 (m, 2H), 1.02 (t, J = 7.52 Hz, 3H) 
13C-NMR  (100 MHz, CDCl3), see page 90 
δ 144.99, 133.60, 129.86, 128.29, 91.90, 71.35, 58.89, 21.78, 13.30, 
12.49 
  
Me
OH
B. TsCl (1.25 equiv.) 
C. KOH (5.0 equiv.)
Et2O, r.t
Me
OTs
56 89%A. 55 (1.0 equiv.)
 54 
octa-2,5-diyn-1-ol (57) 
 
 In a 100 mL round-bottom flask, A (2.51 g, 10.53 mmol, 1 equiv.) was dissolved in 
25 mL of DMF. C (2.01 g, 10.53 mmol, 1.0 equiv.), D (2.18 g, 15.80 mmol, 1.5 equiv.), 
and E (3.89 g, 10.53 mmol, 1.0 equiv.) were then added into the flask. The reaction 
mixture was cooled to 0°C, and B (708.60 mg, 12.64 mmol, 1.2 equiv.) was added 
dropwise. The reaction mixture was returned to room temperature, and stirred overnight. 
Next, the reaction mixture was cooled to 0°C, 20 mL cold water and 150 mL of saturated 
NH4Cl was added sequentially. The mixture was extracted three times with Et2O. The 
organic layers were combined, washed with brine, dried over MgSO4, filtered and 
concentrated under reduced pressure. The residual oil was purified by flash 
chromatography using ethyl acetate and hexane (30:70) as eluent to afford 57 as a yellow 
oil (816.20 mg, 76% yield). The 1H-NMR and 13C-NMR data is in accordance with that 
previously reported in the literature.131 
1H-NMR  (400 MHz, CDCl3), see page 91 
   4.27 (m, 2H), 3.19 (m, 2H), 2.18 (m, 2H), 1.12 (t, J = 2.16 Hz, 3H) 
 
13C-NMR  (100 MHz, CDCl3), see page 92 
   δ 82.58, 80.93, 78.48, 72.81, 51.36, 13.92, 12.45, 9.92 
  
C. CuI (1.0 equiv.)
D. K2CO3 (1.5 equiv.)
E. TBAI (1.0 equiv.)
DMF, r.t.
Me
OH
57 74%
OH
Me
OTs
A. 56 (1.0 equiv.) B. 1.2 equiv.
 55 
1-bromoocta-2,5-diyne (58) 
 
A 100 mL round-bottom oven-dried flask was charged with a magnetic stirring bar 
and filled with argon. A (1.00 g, 8.19 mmol, 1.0 equiv.) and B (2.99 g, 9.01 mmol, 1.1 
equiv.) were dissolved in 20 mL of DCM in the flask. C (2.36 g, 9.01 mmol, 1.1 equiv.) in 
10 mL of DCM was then added dropwise to the reaction mixture. After overnight stirring 
at room temperature, the solvent was removed by using rotary evaporator, the residual 
mixture was purified directly using flash chromatography with ethyl acetate and hexane 
(5:95) as eluent to afford 58 as a pale yellow oil (1.27 g, 84% yield). The 1H-NMR and 13C-
NMR data is in accordance with that previously reported in the literature.148 
1H-NMR  (600 MHz, CDCl3), see page 93 
δ 3.92 (m, 2H), 3.21 (m, 2H), 2.17 (m, 2H), 1.12 (td, J = 7.44 Hz, 1.67 
Hz, 3H) 
13C-NMR  (150 MHz, CDCl3), see page 94 
δ 82.83, 82.25, 75.40, 72.32, 14.97, 13.94, 12.49, 12.49, 10.22 
  
B. CBr4 (1.1 equiv.)
C. PPh3 (1.1 equiv.)
DCM, 0℃
Me
OH
A. 57 (1.0 equiv) 58 84%
Me
Br
 56 
trimethyl(trideca-1,4,7,10-tetrayn-1-yl)silane (60) 
 
In a 200 mL round-bottom flask, A (1.29 g, 6.87 mmol, 1 equiv.) was dissolved in 
60 mL of DMF. C (1.99 g, 10.46 mmol, 1.5 equiv.), D (1.93 g, 13.94 mmol, 2.0 equiv.), 
and E (1.57 g, 10.46 mmol, 1.5 equiv.) were then added into the flask. The reaction 
mixture was cooled to 0°C, and B (1.23 g, 9.06 mmol, 1.3 equiv.) was added dropwise. 
The reaction mixture was returned to room temperature and stirred overnight. Next, the 
reaction mixture was cooled to 0°C, 20 mL cold water and 150 mL of saturated NH4Cl was 
added sequentially. The mixture was extracted three times with Et2O. The organic layers 
were combined, washed with brine, dried over MgSO4, filtered and concentrated under 
reduced pressure to afford 60 as a red oil (1.43 g, 85% yield). The crude 60 was unstable 
and used for the next step immediately. 
1H-NMR  (300 MHz, CDCl3), see page 95 
3.22 - 3.13 (m, 6H), 2.22 – 2.13 (m, 6H), 1.12 (t, J = 7.50 Hz, 3H) 
  
Me
TMS
60 85% (crude)A. 58 (1.0 equiv.)
TMS H
Me
Br
B. 1.3 equiv.
C. CuI (1.5 equiv.)
D. K2CO3 (2.0 equiv.)
E. NaI (1.5 equiv.)
DMF, r.t.
 57 
trimethyl((4Z,7Z,10Z)-trideca-4,7,10-trien-1-yn-1-yl)silane (61) 
 
 A 125 mL round-bottomed flask was charged a magnetic stirring bar and B (301.1 
mg, 1.21 mmol, 0.2 equiv.). The flask was purged with H2 gas three times by vacuum-H2 
cycle. 20 mL of 95% EtOH (all EtOH used was degassed by freeze-pump-thaw method) 
was introduced into the flask under constant supply of H2 gas flow. C (45.77 mg, 1.21 
mmol, 0.2 equiv.) was pre-dissolved in 5 mL of 95% EtOH, and introduced into the reaction 
flask dropwise, and the reaction mixture turned to black. After 30 minutes of stirring, D 
(109.38 mg, 1.82 mmol, 0.4 equiv.) in 1 mL of 95% EtOH was then added into the reaction 
mixture. Next, A (1.46 g, 6.07 mmol, 1.0 equiv.) in 2 mL of 95% EtOH was introduced into 
the reaction mixture, and the flask was then sealed and equipped with an H2 balloon. After 
overnight stirring, the reaction mixture was filtered through a pad of Celite and rinsed with 
ether. The filtrate was concentrated under reduced pressure, and purified by flash 
chromatography with pentane as eluent to afford 61 as a colorless oil (388.50 mg, 26% 
yield). 
1H-NMR (600 MHz, CDCl3), see page 96 
δ 5.48-5.29 (m, 6H), 3.02 (d, J = 4.74 Hz, 2H), 2.84-2.79 (m, 4H), 2.06 (m, 
2H), 0.98 (t, J = 7.56 Hz, 3H), 0.15 (s, 9H) 
13C-NMR (150 MHz, CDCl3), see page 97 
δ 132.28, 130.02, 129.11, 127.38, 127.07, 124.44, 105.20, 84.48, 25.72, 
25.70, 20.72, 18.56, 14.41, 0.24 
HRMS (EI) mass [M+H+]+ calculated: 247.2 Da; found: 247.2 Da  
 
Me
TMSB. Ni(OAC)2ż4H2O (0.2 equiv.)
C. NaBH4 (0.2 equiv.)
D. ethylenediamine (0.4 equiv)
H2 balloon, 95% EtOH
26%61
Me
TMS
A. 60 (1.0 equiv.)
 58 
(4Z,7Z,10Z)-trideca-4,7,10-trien-1-yne (5) 
 
 
 A 25 mL round-bottomed flask was charged with a magnetic stirring bar and 5 mL 
of THF/MeOH (1:1), A (100.0 mg, 0.41 mmol, 1.0 equiv.), and B (170.0 mg, 1.23 mmol, 
3.0 equiv.). After the reaction mixture was stirred at room temperature for three hours, it 
was filtered through a pad of Celite. The filtrate was concentrated under reduced pressure, 
and purified directly by flash chromatography with pentane as eluent to afford 5 as a 
colorless oil (48.8 mg, 68% yield). 
1H-NMR  (600 MHz, CDCl3), see page 98 
δ 5.55-5.30 (m, 6H), 3.00 (m, 2H), 2.88-2.82 (m, 4H), 2.10 (pentet, J 
= 7.57 Hz, 2H), 2.01 (t, J = 2.72 Hz, 1H), 1.00 (t, J = 7.54 Hz, 3H) 
13C-NMR  (150 MHz, CDCl3), see page 99 
δ 132.39, 130.42, 129.29, 127.33, 127.11, 124.22, 82.84, 68.35, 
25.78, 20.81, 17.12, 14.50 
HRMS (EI)  mass [M+H] calculated: 175.14813 Da; found: 175.14802 Da  
 
  
B. K2CO3 (3.0 equiv.)
MeOH, r.t.
Me
H
5 68%
Me
TMS
A. 61 (1.0 equiv.)
 59 
(4Z,8E,13Z,16Z,19Z)-ethyl 7-((tert-butyldiphenylsilyl)oxy)docosa-4,8,13,16,19-pentaen-
10-ynoate (2) 
 
 
 A 10 mL oven-dried round-bottomed flask was filled with argon. Two mL of freshly-
distilled diisopropylamine, A (67.51 mg, 0.12 mmol, 1.0 equiv.) and C (13.87 mg, 0.012 
mmol, 0.1 equiv.) were added into the flask. The resulting solution was stirred for 30 
minutes. Next, D (11.43 mg, 0.06 mmol, 0.5 equiv.) and B (30.0 mg, 0.16 mmol, 1.3 equiv.) 
were added. After overnight stirring, the mixture was diluted with Et2O, followed by adding 
saturated NH4Cl. The aqueous layer was extracted with Et2O (X 3). The organic layers 
were combined, washed with brine, dried over MgSO4, filtered and concentrated. The 
residual oil was purified by flash chromatography using ethyl acetate and hexane (5:95) 
as eluent to afford 2 as a colorless oil (69.9 mg, 96% yield). 
1H-NMR (400 MHz, CDCl3), see page 100 
δ 7.68 – 7.61 (m, 4H), 7.43 – 7.34 (m, 6H), 6.01 (dd, J = 15.84 Hz, 5.74 Hz, 
1H), 5.54 (dd, J = 15.83 Hz, 1.51 Hz, 1H), 5.50 – 5.26 (m, 8H), 4.20 (m, 1H), 
4.10 (q, J = 7.13 Hz, 2H), 3.09 – 3.08 (m, 2H), 2.86 – 2.80 (m, 2H), 2.28 – 
2.04 (m, 2H), 1.24 (t, J = 7.13 Hz, 3H), 1.06 (s, 9H), 0.98 (t, J = 7.53 Hz, 3H) 
13C-NMR (150 MHz, CDCl3), see page 101 
173. 21, 144.09, 136.06, 136.04, 134.30, 133.81, 132.29, 130.00, 129.84, 
129.79, 129.12, 127.72, 127.69, 127.42, 127.07, 125.80, 124.69, 110.05, 
88.58, 78.73, 73.22, 60.40, 35.63, 34.24, 29.86, 27.18, 25.70, 22.99, 20.72, 
18.50, 18.06, 14.41. 
HRMS (EI) mass [M+H] calculated: 609.37585 Da; found: 609.37614 Da  
Me
I
O
OEt
O C. Pd(Ph3)4 (10mol%)
D. CuI (50mol%)
diisopropylamine, r.t.
2 96%
A. 4 (1.0 equiv.)
B. 5 (1.3 equiv.)
O
OEt
O
TBDPS TBDPS
 60 
(4Z,8E,10Z,13Z,16Z,19Z)-ethyl 7-((tert-butyldiphenylsilyl)oxy)docosa-4,8,10,13,16,19-
hexaenoate (1) 
 
The Preparation of Zn(Cu/Ag) 3.0 g of Zn dust was freshly purified by washing 
sequentially with 1 M HCl twice, distilled water, EtOH, and Et2O (the wash solutions were 
removed each time by filtration). The purified zinc dust was transferred into a 100 mL 
round-bottomed flask that was charged with a magnetic stirring bar and filled with argon. 
30 mL of distilled water was added, and 300 mg of Cu(OAc)2·H2O was added to the 
vigorously stirred suspension. After 15 minutes of stirring, 300 mg of AgNO3 was added 
to the suspension. After another 30 minutes stirring, the water was filtered off under strict 
argon atmosphere, the wet Zn(Cu/Ag) cake was washed sequentially with acetone and 
Et2O, the solvents were removed each time by filtration. The fresh Zn(Cu/Ag) was then 
dried under vacuum.  
The Synthesis of 1 The fresh Zn(Cu/Ag) was transferred to a 100 mL argon-filled 
round-bottom flask. 50 mL of MeOH: H2O (1:1) was added into the flask. A (150.0 mg, 
0.25 mmol) in 1.5 mL of dioxane was added to the suspension of Zn(Cu/Ag). The reaction 
mixture was stirred at 45°C for 6 hours, then 0.2 mL of 1 M HCl was added to the reaction 
mixture. After overnight stirring, another 0.2 mL of 1 M HCl was added to the reaction. 
Aliquots were taken to check the consumption of A by 1H-NMR. Until the reaction reached 
full conversion, 0.2 mL of 1 M HCl was added to the reaction mixture every 16 to 24 hours. 
After the completion, the reaction mixture was filtered through Celite, the cake was rinsed 
with MeOH and then Et2O thoroughly. The filtrate was concentrated under reduced 
O
OEt
O
Si
Ph
tBu Ph
 Zn(Cu/Ag)
MeOH/H2O/dioxane 
(1:1:0.5)
45℃, 2 days
spiked with 1M HCl
O
OEt
O
Me
Si
Ph
Ph
tBu
1 quantitative
Me
A. 2 (1.0 equiv.)
 61 
pressure until most of the organic solvent was removed. The residual mixture was diluted 
with Et2O, the organic layer was washed with water, then brine (X2), dried over MgSO4, 
filtered and concentrated under reduced pressure. The residual oil was purified by flash 
chromatography using ethyl acetate and hexane (5:95) as eluent to afford 1 as a colorless 
oil (154.1 mg, 100% yield). 
1H-NMR (600 MHz, CDCl3), see page 102 
δ 7.69 – 7.64 (m, 4H), 7.42 – 7.33 (m, 6H), 6.22 (dd, J = 15.11 Hz, 11.09 Hz, 
1H), 5.89 (t, J = 10.82 Hz, 1H), 5.61 (dd, J = 15.12 Hz, 6.54 Hz, 1H), 5.41 – 
5.28 (m, 9H), 4.23 (m, 1H), 4.11 (q, J = 7.14 Hz, 2H), 2.83 – 2.78 (m, 6H), 
2.32 – 2.28 (m, 1H), 2.25 – 2.22 (m, 3H), 2.20 – 2.16 (m, 2H), 2.05 (m, 2H), 
1.24 (t, J = 7.22 Hz, 3H), 0.97 (t, J = 7.53 Hz, 3H) 
13C-NMR (150 MHz, CDCl3), see page 103 
δ 173. 25, 136.14, 136.08, 135.90, 134.48, 134.21, 132.20, 129.73, 129.66, 
129.62, 128.78, 128.62, 128.34, 127.98, 127.64, 127.54, 127.17, 126.45, 
125.39, 73.87, 60.40, 36.09, 34.32, 29.85, 27.19, 26.14, 25.76, 25.69, 23.06, 
20.70, 19.49, 14.40 
HRMS (EI) mass [M+H] calculated: 611.39150 Da; found: 611.39185 Da  
 
  
 62 
(4Z,8E,10Z,13Z,16Z,19Z)-ethyl 7-hydroxydocosa-4,8,10,13,16,19-hexaenoate (62) 
 
A 25 mL round-bottom flask was charged with a magnetic stirring bar, and A (130.0 
mg, 0.21 mmol, 1 equiv.) in 10 mL THF, B (1M in THF, 0.24 mL, 0.23 mmol, 1.1 equiv.) 
was added to the solution drop-wise. The mixture was stirred at room temperature 
overnight. Next, the reaction mixture quenched by the addition of water, the aqueous layer 
was separated and extracted with ethyl acetate (X 3). The organic phase was then washed 
over brine, and dried over MgSO4, filtered and concentrated under reduced pressure. The 
residual oil was purified by flash chromatography using ethyl acetate and hexane (15:85) 
as eluent to afford 62 as a colorless oil (61.4 mg, 78% yield). 
1H-NMR (700 MHz, CDCl3), see page 104 
δ 6.56 (dd, J = 15.07 Hz, 11.23 Hz, 1H), 6.02 – 5.99 (m, 1H), 5.73 (dd, J = 
14.71 Hz, 6.44 Hz, 1H), 5.55 – 5.46 (m, 2H), 5.43 – 5.36 (m, 6H), 5.34 – 
5.30 (m, 1H), 4.24 (m, 1H), 4.13 (q, J = 7.21 Hz, 2H), 2.97 (m, 2H), 2.85 (m, 
2H), 2.81 (m, 2H), 2.42 – 2.33 (m, 6H), 2.08 (m, 2H), 1.25 (t, J = 7.03 Hz, 
3H), 0.98 (t, J = 7.54 Hz, 3H) 
13C-NMR (150 MHz, CDCl3), see page 105 
δ 173.37, 135.88, 132.25, 131.23, 130.48, 128.81, 128.17, 127.96, 127.78, 
127.17, 126.32, 125.61, 72.05, 60.59, 35.57, 34.13, 26.27, 25.82, 25.72, 
23.02, 20.72, 14.41, 14.39 
HRMS (EI) mass [M+NH4] calculated: 390.30027 Da; found: 390.30028 Da  
OH
OEt
O
Me
62 78%
THF, r.t.
O
OEt
O
Me
Si
Ph
Ph
tBu
A. 1 (1 equiv.)
B. TBAF (1.1 equiv.)
 63 
(4Z,8E,10Z,13Z,16Z,19Z)-7-hydroxydocosa-4,8,10,13,16,19-hexaenoic acid (±) 7-HDHA 
 
In a 10 mL argon-filled round-bottomed flask, A (41.0 mg, 0.11 mmol, 1.0 equiv.) 
was dissolved in 3 mL of H2O: THF (1:1), B (39.5mg, 1.65 mmol, 15.0 equiv.) was then 
added to the flask. The reaction was stirred at room temperature overnight. The reaction 
mixture was then cooled to 0°C, 1 M HCl was then added dropwise until the aqueous layer 
was acidified. The aqueous layer was extracted with ethyl acetate exhaustively. The 
organic phase was then washed over brine, and dried over MgSO4, filtered and 
concentrated. The residual oil was purified by flash chromatography using ethyl acetate 
and hexane (50:50) as eluent to afford (±) 7-HDHA as a colorless oil (30.4 mg, 80% yield). 
1H-NMR (700 MHz, CDCl3), see page 106 
δ 6.55 (dd, J = 15.13 Hz, 11.06 Hz, 1H), 6.00 (t, J = 10.86 Hz, 1H), 5.72 (dd, 
J = 15.16 Hz, 6.41 Hz, 1H), 5.53 (m, 1H), 5.48 (m, 1H), 5.43 – 5.35 (m, 6H), 
5.32 (m, 1H), 4.25 (m, 1H), 2.97 (t, J = 6.93 Hz, 2H), 2.85 (t, J = 6.41 Hz, 
2H), 2.81 (t, J = 6.51 Hz, 2H), 2.45 – 2.33 (m, 6H), 2.09 – 2.06 (m, 2H), 0.97 
(t, J = 7.84 Hz, 3H), the carboxylic acid proton was not observed in this 
spectrum.  
13C-NMR (176 MHz, CDCl3), see page 107 
δ 177.67, 135.65, 132.25, 130.93, 130.58, 128.80, 128.10, 127.94, 127.74, 
127.14, 126.56, 125.69, 72.10, 35.46, 33.60, 26.25, 25.80, 25.70, 22.75, 
20.71, 14.42 
HRMS (ESI) mass [M-H]- calculated: 343.2268 Da; found: 343.2278 Da  
OH
OH
O
Me
(±) 7-HDHA 80%
B. LiOH (15.0 equiv.)
THF/H2O (1:1), r.t.
OH
OEt
O
Me
A. 62 (1.0 equiv.)
 64 
4.3 COSY and HMBC Correlations of (±) 7-HDHA 
(4Z,8E,10Z,13Z,16Z,19Z)-7-hydroxydocosa-4,8,10,13,16,19-hexaenoic acid (±) 7-HDHA 
COSY correlations 
 
 
a`Recorded at 700 MHz,  
         b Assignments based on COSY, HSQC, HMBC, and HSQC-TOCSY. 
         c Only those correlations which could be unambiguously assigned are recorded.  
  
OH
OH
O
1
23
4
5
7
68
910
11
12
13
14
15
16
17
18
19
20
21
22
Proton No. 1H δ (ppm) (mult, J (Hz))a,b COSY Correlationsc 
 H-2 part of the m at 2.45 – 2.33  
H-3 part of the m at 2.45 – 2.33  
H-4 5.48 (m, 1H) H-5 
H-5 5.53 (m, 1H) H-4 
H-6 part of the m at 2.45 – 2.33  
H-7 4.25 (m, 1H) H-8  
H-8 5.72 (dd, J = 15.16 Hz, 6.41 Hz) H-7, H-9 
H-9 6.55 (dd, J = 15.13 Hz, 11.06 Hz) H-8, H-10 
H-10 6.00 (t, J = 10.86 Hz) H-9, H-12 
H-11 part of the m at 5.43 – 5.35  
H-12 2.97 (t, J = 6.93 Hz)  
H-13 part of the m at 5.43 – 5.35  
H-14 part of the m at 5.43 – 5.35  
H-15 2.85 (t, J = 6.41 Hz)  
H-16 part of the m at 5.43 – 5.35  
H-17 part of the m at 5.43 – 5.35  
H-18 2.81 (t, J = 6.51 Hz) H-19 
H-19 5.32 (m) H-18 
H-20 part of the m at 5.43 – 5.35  
H-21 2.09 – 2.06 (m) H-22 
H-22 0.97 (t, J = 7.84 Hz) H-21 
 65 
(4Z,8E,10Z,13Z,16Z,19Z)-7-hydroxydocosa-4,8,10,13,16,19-hexaenoic acid (±) 7-HDHA 
HMBC correlations 
 
    a Recorded at 700 MHz,  
    b Assignments based on COSY, HSQC, HMBC, and HSQC-TOCSY, 
    c Only those correlations which could be unambiguously assigned are recorded. 
  
OH
OH
O
1
23
4
5
7
68
910
11
12
13
14
15
16
17
18
19
20
21
22
Carbon No. 13C δ (ppm) 1H δ (ppm) (mult, J (Hz))a,b HMBC Correlationsc 
2 33.60 H-2 : part of the m at 2.45 – 2.33 H-3 
3 22.75 H-3 : part of the m at 2.45 – 2.33 H-4 
4 130.93 H-4: 5.48 (m, 1H) H-3 
5 126.56 H-5: 5.53 (m, 1H) H-6, H-7 
6 35.46 H-6 : part of the m at 2.45 – 2.33 H-5, H-7 
7 72.10 H-7: 4.25 (m, 1H) H-9, H-8, H-6 
8 135.65 H-8 : 5.72 (dd, J = 15.16, 6.41 Hz) H-10, H-7, H-6 
9 125.69 H-9 : 6.55 (dd, J = 15.13, 11.06 Hz) H-8, H-7,  
10 128.10 H-10 : 6.00 (t, J = 10.86 Hz) H-8, H-9, H-12 
11 130.58 H-11 : part of the m at 5.43 – 5.35 H-9, H-12 
12 26.25 H-12 : 2.97 (t, J = 6.93 Hz) H-10 
13 127.74 H-13 : part of the m at 5.43 – 5.35 H-12 
14 part of 128.80 H-14 : part of the m at 5.43 – 5.35  
15 25.80 H-15 : 2.85 (t, J = 6.41 Hz)  
16 127.94 H-16 : part of the m at 5.43 – 5.35 H-15, H-18 
17 part of 128.80 H-17 : part of the m at 5.43 – 5.35  
18 25.70 H-18 : 2.81 (t, J = 6.51 Hz) H-19 
19 127.14 H-19 : 5.32 (m) H-18, H-21 
20 132.25 H-20 : part of the m at 5.43 – 5.35 H-18, H-21, H-22 
21 20.71 H-21 : 2.09 – 2.06 (m) H-22 
22 14.42 H-22 : 0.97 (t, J = 7.84 Hz) H-21 
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Appendix: 1H and 13C NMR Spectra 
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